1. Scrip

Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years

Next Competitor Likely Years Behind

 
• By Mandy Jackson

Neurocrine will launch Crenessity for adults and children with classic congenital adrenal hyperplasia in less than a week, with pricing available then, adding its second commercial product.

Neurocrine won FDA approval for Crenessity two weeks earlier than expected (Shutterstock)

Neurocrine Biosciences will soon launch its second wholly owned commercial product, Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH), adding what the company sees as another blockbuster opportunity for its portfolio. Analyst expectations for the drug’s sales are mixed, but Neurocrine has a first-to-market advantage in a disease with no new treatments in 70 years and its next competitor is likely a few years away from reaching patients.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip